To get further insights into the actual functions of this new B-cell lymphoma marker and identify members of its oncogenic network that could represent novel predictive factors of DLBCL clinical outcome, we characterized the CYCLON protein interactome and identified NPM1 as a joint marker that further improves CYCLON-based stratification of high-risk DLBCL patients. Here, CCDC86 is linked to B-cell non-Hodgkin lymphoma.